The effect of 18F-florbetapir dose reduction on region-based classification of cortical amyloid deposition

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 11, 2014, Pages 2144-2149

  Herholz, K ^a   Evans, R ^a   Anton Rodriguez, J ^a   Hinz, R ^a   Matthews, J C ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

18F florbetapir; Alzheimer s disease; Amyloid; Bootstrapping; PET

Indexed keywords

AMYLOID; ANILINE DERIVATIVE; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MODEL; BRAIN CORTEX; DIAGNOSTIC USE; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIATION RESPONSE; SCINTISCANNING; SIGNAL NOISE RATIO;

AGED; ALZHEIMER DISEASE; AMYLOID; ANILINE COMPOUNDS; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, RADIATION; ETHYLENE GLYCOLS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; POSITRON-EMISSION TOMOGRAPHY; SIGNAL-TO-NOISE RATIO;

EID: 84930984346     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2842-3     Document Type: Article

References (19)

1. Albert MS, Dekosky ST, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–9.
2. Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26(3):839–51.
3. Barrett HH, Myers KJ. Foundations of image science. Hoboken: Wiley-Interscience; 2004.
4. Clark CM, Pontecorvo MJ, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11(8):669–78.
5. Comtat C, Sureau FC et al. (2009). Image-based resolution modeling for the HRRT OSEM reconstructions software 2008 I.E. Nuclear Science Symposium and Medical Imaging Conference 1–9: 3395–3398
6. Duara R, Loewenstein DA, et al. Amyloid positron emission tomography with (18)F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer’s disease. Alzheimers Dement. 2013;9(3):295–301.
7. Edison P, Carter SF, et al. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET. Neuroimage. 2013;70:423–33.
8. Fleisher AS, Chen K, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68(11):1404–11.
9. Grundman M, Pontecorvo MJ, et al. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord. 2013;27(1):4–15.
10. Hammers A, Allom R, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19:224–47.
11. Herholz K, Ebmeier KP. Clinical amyloid imaging in Alzheimer’s disease. Lancet Neurol. 2011;10:667–70.
12. Jenkinson M, Bannister P, et al. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage. 2002;17(2):825–41.
13. Joshi AD, Pontecorvo MJ, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer’s disease and cognitively normal subjects. J Nucl Med. 2012;53(3):378–84.
14. Landau SM, Mintun MA, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72(4):578–86.
15. Lartizien C, Aubin JB, et al. Comparison of bootstrap resampling methods for 3-D PET imaging. IEEE Trans Med Imaging. 2010;29(7):1442–54.
16. McKhann GM, Knopman DS, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.
17. Mourik JE, Lubberink M, et al. In vivo validation of reconstruction-based resolution recovery for human brain studies. J Cereb Blood Flow Metab. 2010;30(2):381–9.
18. Prestia A, Caroli A, et al. Diagnostic accuracy of markers for prodromal Alzheimer’s disease in independent clinical series. Alzheimers Dement. 2013;9(6):677–86.
19. Watson CC, Casey ME, et al. Optimizing injected dose in clinical PET by accurately modeling the counting-rate response functions specific to individual patient scans. J Nucl Med. 2005;46(11):1825–34.